Novonesis (Novozymes) B (FRA:NZM) Valuation Rank


FRA:NZM Novonesis (Novozymes) B FRA:NZM
91 GF Score
Price €56.00
GF Value €55.83
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Novonesis (Novozymes) B Valuation Rank Related Terms

FRA:NZM
91GF Score
Novonesis (Novozymes) B FRA:NZM
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novonesis (Novozymes) B (FRA:NZM) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be overvalued. The current stock price of €56.00 is trading 0.3% above its estimated GF Value™ of €55.83. GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.

Key valuation signals for FRA:NZM:

  • Valuation Rank:
  • GF Value™: €55.83 vs. price of €56.00 (0.3% above fair value)
  • GF Score™: 91/100 with 6 warning signs

No single metric tells the full story. See the FRA:NZM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
91GF Score

Get the complete analysis for FRA:NZM

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€56.00
Price
€55.83
GF Value